[Congenital solid tumors. A thirteen-year review]

A Albert1, O Cruz, A Montaner

  • 1Servicio de Cirugía Pediátrica, Unitat Integrada Hospital Sant Joan de Déu-H. Clínic, Universitat de Barcelon, Barcelona.

Insights

Congenital tumors are rare but differ from those in older children. Surgical resection is the primary treatment, with most cases not requiring chemotherapy, indicating a generally favorable prognosis.

Area of Science:

  • Pediatric Oncology
  • Neonatal Medicine
  • Surgical Pathology

Background:

  • Congenital tumors represent a small fraction (0.5-2%) of childhood neoplasms.
  • These tumors exhibit distinct characteristics in terms of type, incidence, natural history, and treatment response compared to tumors in older children.

Purpose of the Study:

  • To report institutional experience with congenital tumors over a 13-year period.
  • To analyze the types, diagnoses, treatments, and outcomes of solid tumors in neonates.

Main Methods:

  • Retrospective review of neonates (< 31 days old) diagnosed with solid tumors between January 1990 and December 2002.
  • Analysis of diagnostic methods, tumor types, staging, treatment modalities, and patient outcomes.

Main Results:

  • Twenty-seven neonates were diagnosed with tumors; 48% were detected prenatally.
  • Neuroblastoma (37%) and teratomas (30%) were the most common. Surgical resection was the primary treatment (68%).
  • The mortality rate was 11%, with causes including surgical complications, airway obstruction, and craniopharyngioma.

Conclusions:

  • Prenatal ultrasound aids in earlier diagnosis of congenital tumors.
  • Congenital tumors generally have a more benign natural history than in older children, with exceptions for CNS and large/obstructing tumors.
  • Complete surgical excision is the preferred treatment; adjuvant chemotherapy is often unnecessary. Histological type is not always predictive of outcome.
Abstract

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...